Immunitybio Inc. (IBRX)

$3.4

-0.17

(-4.76%)▲

Market is closed - opens 7 PM, 04 Oct 2024

Performance

  • $3.38
    $3.51
    $3.40
    downward going graph

    0.59%

    Downside

    Day's Volatility :3.7%

    Upside

    3.13%

    downward going graph
  • $1.25
    $10.53
    $3.40
    downward going graph

    63.24%

    Downside

    52 Weeks Volatility :88.13%

    Upside

    67.71%

    downward going graph

Returns

PeriodImmunitybio Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-40.76%
7.5%
0.0%
6 Months
-34.85%
6.9%
0.0%
1 Year
159.23%
20.9%
0.0%
3 Years
-62.2%
21.0%
-21.1%

Highlights

Market Capitalization
2.7B
Book Value
- $1.01
Earnings Per Share (EPS)
-0.96
Wall Street Target Price
6.38
Profit Margin
0.0%
Operating Margin TTM
-9487.39%
Return On Assets TTM
-61.04%
Return On Equity TTM
0.0%
Revenue TTM
1.3M
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
2453.7%
Gross Profit TTM
240.0K
EBITDA
-341.1M
Diluted Eps TTM
-0.96
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.86
EPS Estimate Next Year
-0.74
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
-0.16

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Immunitybio Inc.(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
00
00
Hold
2
3
3
Sell
00
3
3

Analyst Forecast

What analysts predicted

Upside of 87.65%

Current $3.40
Target $6.38

Company Financials

FY18Y/Y Change
Revenue
47.0K
↑ 4.44%
Net Income
-96.2M
↓ 0.2%
Net Profit Margin
-204.7K%
↑ 9537.16%
FY19Y/Y Change
Revenue
2.2M
↑ 4585.11%
Net Income
-160.2M
↑ 66.44%
Net Profit Margin
-7.3K%
↑ 197462.87%
FY20Y/Y Change
Revenue
605.0K
↓ 72.52%
Net Income
-224.2M
↑ 39.98%
Net Profit Margin
-37.1K%
↓ 29782.4%
FY21Y/Y Change
Revenue
934.0K
↑ 54.38%
Net Income
-349.8M
↑ 56.05%
Net Profit Margin
-37.5K%
↓ 401.26%
FY22Y/Y Change
Revenue
240.0K
↓ 74.3%
Net Income
-417.3M
↑ 19.29%
Net Profit Margin
-173.9K%
↓ 136426.37%
FY23Y/Y Change
Revenue
622.0K
↑ 159.17%
Net Income
-583.2M
↑ 39.75%
Net Profit Margin
-93.8K%
↑ 80121.92%
Q1 FY23Q/Q Change
Revenue
360.0K
↑ 393.15%
Net Income
-151.2M
↑ 39.54%
Net Profit Margin
-42.0K%
↑ 106402.34%
Q2 FY23Q/Q Change
Revenue
41.0K
↓ 88.61%
Net Income
-137.9M
↓ 8.79%
Net Profit Margin
-336.3K%
↓ 294300.8%
Q3 FY23Q/Q Change
Revenue
82.0K
↑ 100.0%
Net Income
-95.6M
↓ 30.68%
Net Profit Margin
-116.6K%
↑ 219726.83%
Q4 FY23Q/Q Change
Revenue
139.0K
↑ 69.51%
Net Income
-233.4M
↑ 144.18%
Net Profit Margin
-167.9K%
↓ 51344.5%
Q1 FY24Q/Q Change
Revenue
40.0K
↓ 71.22%
Net Income
-134.1M
↓ 42.54%
Net Profit Margin
-335.3K%
↓ 167364.59%
Q2 FY24Q/Q Change
Revenue
1.0M
↑ 2517.5%
Net Income
-134.6M
↑ 0.34%
Net Profit Margin
-12.9K%
↑ 322420.16%
FY18Y/Y Change
Total Assets
182.0M
↓ 27.35%
Total Liabilities
35.9M
↑ 13.76%
FY19Y/Y Change
Total Assets
143.1M
↓ 21.34%
Total Liabilities
22.4M
↓ 37.56%
FY20Y/Y Change
Total Assets
221.4M
↑ 54.68%
Total Liabilities
339.9M
↑ 1414.31%
FY21Y/Y Change
Total Assets
468.9M
↑ 111.81%
Total Liabilities
712.8M
↑ 109.73%
FY22Y/Y Change
Total Assets
362.4M
↓ 22.72%
Total Liabilities
812.2M
↑ 13.94%
FY23Y/Y Change
Total Assets
504.5M
↑ 39.21%
Total Liabilities
1.1B
↑ 34.26%
Q1 FY23Q/Q Change
Total Assets
343.4M
↓ 5.23%
Total Liabilities
875.1M
↑ 7.75%
Q2 FY23Q/Q Change
Total Assets
291.2M
↓ 15.19%
Total Liabilities
936.4M
↑ 7.0%
Q3 FY23Q/Q Change
Total Assets
432.4M
↑ 48.48%
Total Liabilities
843.1M
↓ 9.97%
Q4 FY23Q/Q Change
Total Assets
504.5M
↑ 16.66%
Total Liabilities
1.1B
↑ 29.34%
Q1 FY24Q/Q Change
Total Assets
400.7M
↓ 20.57%
Total Liabilities
1.1B
↑ 0.12%
Q2 FY24Q/Q Change
Total Assets
444.3M
↑ 10.89%
Total Liabilities
1.1B
↑ 4.58%
FY18Y/Y Change
Operating Cash Flow
-63.4M
↑ 29.93%
Investing Cash Flow
25.7M
↓ 74.2%
Financing Cash Flow
-771.0K
↓ 97.8%
FY19Y/Y Change
Operating Cash Flow
-152.1M
↑ 139.99%
Investing Cash Flow
-6.3M
↓ 124.59%
Financing Cash Flow
114.3M
↓ 14922.18%
FY20Y/Y Change
Operating Cash Flow
-171.7M
↑ 12.9%
Investing Cash Flow
-1.4M
↓ 78.29%
Financing Cash Flow
150.7M
↑ 31.85%
FY21Y/Y Change
Operating Cash Flow
-274.4M
↑ 59.8%
Investing Cash Flow
-84.9M
↑ 6091.54%
Financing Cash Flow
505.4M
↑ 235.45%
FY22Y/Y Change
Operating Cash Flow
-337.5M
↑ 22.99%
Investing Cash Flow
27.3M
↓ 132.16%
Financing Cash Flow
233.6M
↓ 53.78%
Q1 FY23Q/Q Change
Operating Cash Flow
-84.3M
↓ 7.07%
Investing Cash Flow
-8.5M
↓ 55.1%
Financing Cash Flow
76.9M
↓ 30.06%
Q2 FY23Q/Q Change
Operating Cash Flow
-79.8M
↓ 5.38%
Investing Cash Flow
-8.6M
↑ 1.41%
Financing Cash Flow
43.4M
↓ 43.54%

Technicals Summary

Sell

Neutral

Buy

Immunitybio Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Immunitybio Inc.
Immunitybio Inc.
0.54%
-34.85%
159.23%
-62.2%
-88.55%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-10.06%
10.55%
30.05%
89.27%
274.48%
Novo Nordisk A/s
Novo Nordisk A/s
-12.62%
-6.24%
35.65%
145.66%
372.59%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.37%
82.34%
59.06%
41.03%
258.58%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.23%
13.76%
34.75%
162.16%
172.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Immunitybio Inc.
Immunitybio Inc.
NA
NA
NA
-0.86
0.0
-0.61
NA
-1.01
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.85
27.85
1.43
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.39
40.39
1.82
3.45
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.56
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Immunitybio Inc.
Immunitybio Inc.
Buy
$2.7B
-88.55%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$115.9B
274.48%
27.85
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$531.4B
372.59%
40.39
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$35.3B
258.58%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.0B
172.77%
32.84
-4.74%

Insights on Immunitybio Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 40.0K → 1.04M (in $), with an average increase of 96.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -134.10M → -134.56M (in $), with an average decrease of 0.3% per quarter

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 42.7% return, outperforming this stock by 105.5%

Institutional Holdings

  • Vanguard Group Inc

    1.99%

  • BlackRock Inc

    1.64%

  • State Street Corp

    1.13%

  • Geode Capital Management, LLC

    0.56%

  • JANE STREET GROUP, LLC

    0.25%

  • UBS Asset Mgmt Americas Inc

    0.23%

Corporate Announcements

  • Immunitybio Inc. Earnings

    Immunitybio Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer (‘nk’) and t cells, tumoricidal macrophages, and memory t cells.

Organization
Immunitybio Inc.
Employees
622
CEO
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.
Industry
Healthcare

Discover More

FAQs